David J. Clark - Nov 14, 2022 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Medical Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Nov 14, 2022
Transactions value $
$0
Form type
4
Date filed
11/14/2022, 03:43 PM
Next filing
Feb 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +300K $0.00 300K Nov 14, 2022 Common Stock 300K $2.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on November 14, 2022. The 300,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on November 14, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter, through November 14, 2026.